Positive Review from the Drug Safety Monitoring Board (DSMB) on the Ongoing Phase 2 Clinical Trial in Ulcerative Colitis. Positive Opinion for Orphan Drug Designation from the European Medicines Agency in the
- CONNECT1-EDO51 will assess dystrophin levels, exon skipping data and safety data following multiple doses of PGN-EDO51 in patients with mutations amenable to skipping exon 51 - - Initial data. | May 18, 2023
No safety concerns found in first two dose level cohortsEnables progression to highest dosing level in assessment of Ultimovacs' second vaccine technology platform Oslo, 3 February 2022: Ultimovacs
Ultimovacs to Progress to Last Cohort in Phase I Prostate Cancer TENDU study morningstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from morningstar.com Daily Mail and Mail on Sunday newspapers.